BofA Securities Reiterates Buy Rating on Royalty Pharma (RPRX)

February 12, 2026 5:52 AM EST Send to a Friend
BofA Securities analyst Geoff Meacham reiterated a Buy rating and $54.00 price target on Royalty Pharma (NASDAQ: RPRX).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login